Medical News

RSS

Pregnant women with H1N1 more likely to have low birth weight baby

In 2009, the United States was gripped by concern for a new winter threat: the H1N1 strain of influenza. According to research conducted through that winter, pregnant women were right to be concerned.

3 May 2011

VITAS acquires operating assets of Alabama-based Family Comfort Hospice

Chemed Corporation today announced that its VITAS Healthcare Corporation subsidiary has acquired the operating assets of Family Comfort Hospice based in Alabama, effective April 29, 2011.

3 May 2011

Positive Ellex 2RT data demonstrates efficacy in treatment of early Age-Related Macular Degeneration

Ellex Medical Lasers Limited (ASX:ELX) today announced milestone clinical results for its breakthrough Retinal Regeneration Therapy (Ellex 2RT™) for the treatment of Early Age-Related Macular Degeneration (AMD).

2 May 2011

New research shows honey fights drug-resistant germs

Herbal ingredients and natural nutrients are often capable of supporting different functions within the body, and current research is showing that a certain kind of honey may be useful in fighting drug-resistant germs.

2 May 2011

Animal studies reveal new route to treating heart disease

Scientists at Johns Hopkins have shown in laboratory experiments in mice that blocking the action of a signaling protein deep inside the heart’s muscle cells blunts the most serious ill effects of high blood pressure on the heart. These include heart muscle enlargement, scar tissue formation and loss of blood vessel growth.

2 May 2011

Watson introduces generic version of Concerta

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., has launched an authorized generic version of Concerta as part of an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc.

2 May 2011

Caliper first quarter revenue increases 25% to $35.8 million

Caliper Life Sciences, Inc., today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010.

2 May 2011

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Watson Pharmaceuticals, Inc., today announced the U.S. commercial launch of Generess Fe 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods.

2 May 2011

Beijing Kanglian, Dehaier sign cooperation agreement for rural healthcare project

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China today announced that it has signed a cooperation agreement with Beijing Kanglian Medicines Co, Ltd, to develop, operate and implement for a new rural healthcare construction project in Hunan and Anhui provinces.

2 May 2011

InTouch Health launches RP-Xpress telemedicine device

InTouch Health unveiled today the RP-Xpress at the American Telemedicine Association's 16th Annual International Meeting and Exposition in Tampa, FL.

2 May 2011

CHS to acquire Tenet for $7.25 per share

Community Health Systems, Inc. today announced that it has raised its all-cash offer to acquire all outstanding shares of common stock of Tenet Healthcare Corporation to $7.25 per share from $6.00 per share.

2 May 2011

Sorin introduces new VascuClear device for clinicians

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular devices, is proud to announce the introduction of its VascuClear Endoscopic Vessel Harvesting (EVH) system to replace the existing EVH product offering.

2 May 2011

MedRisk introduces dedicated website for claims professionals

MedRisk, Inc., the workers' compensation industry leader in the management of physical medicine services, has announced the launch of its dedicated website for claims professionals.

2 May 2011

Teva signs definitive agreement to acquire Cephalon shares for $6.8 billion

Teva Pharmaceutical Industries Ltd. and Cephalon, Inc. today announced that their Boards of Directors have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction is not conditioned on financing and is expected to be completed in the third quarter of 2011.

2 May 2011

First Edition: May 2, 2011

With Congress due back to work in Washington, D.C., after its spring recess, the next stage of the budget battle is expected to heat up. News reports detail the part Medicare and Medicaid will play in the debate.

2 May 2011

Study evaluates impact of caffeine and technology on adolescent sleep time

Christina Calamaro considers adolescence as more than just a transitional stage between childhood and adulthood. She sees it as an opportunity for positive change.

2 May 2011

USPSTF recommendations negatively impact yearly mammograms among 40-49 year old women

Two new studies reveal that the United States Preventative Services Task Force's recommendation to no longer screen women ages 40-49 for breast cancer using mammograms has begun to negatively affect the number of yearly mammograms performed in this age group and thus decrease the benefits of early detection.

2 May 2011

New OMA President brings commitment to prioritize health care during election

Today, Dr. Stewart Kennedy becomes the 130th President of the Ontario Medical Association and brings with him a commitment to ensure health care is a priority in the upcoming provincial election.

2 May 2011

HPNC offers early childhood development program for kids upto age 5

The Hyde Park Neighborhood Club provides an example of how engaged individuals can sustain communities through long lasting stability.

2 May 2011

FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing two Biologics License Applications for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma.

2 May 2011